Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study

This publication has 25 references indexed in Scilit:

• Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study
  Journal of Clinical Oncology, 2021
• Abiraterone acetate versus bicalutamide in combination with gonadotropin releasing hormone antagonist therapy for high risk metastatic hormone sensitive prostate cancer
  Scientific Reports, 2021
• Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone‐sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study
  International Journal of Urology, 2021
• What is the impact of clinical guidelines on imaging costs?
  Journal of Education and Health Promotion, 2021
• ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer
  Journal of Clinical Oncology, 2019
• Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
  New England Journal of Medicine, 2019
• Efficacy and safety of abiraterone acetate plus prednisone in Japanese patients with newly diagnosed, metastatic hormone-naïve prostate cancer: a subgroup analysis of LATITUDE, a randomized, double-blind, placebo-controlled, Phase 3 study
  Japanese Journal of Clinical Oncology, 2018
• Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer
  New England Journal of Medicine, 2017
• Recent Trends in the Initial Therapy for Newly Diagnosed Prostate Cancer in Japan
  Japanese Journal of Clinical Oncology, 2014
• Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
  New England Journal of Medicine, 2014